Justin Fengler, Chief Financial Officer and Chief Strategy & Operations Officer of GoodRx Holdings, Inc. (NASDAQ:GDRX), filed a Form 4 on September 15, 2026, reporting the vesting of restricted stock units and the withholding of shares to cover taxes on that date.

Key Highlights

  • RSU vesting (first award): 2,335 shares of Class A Common Stock were acquired via RSU conversion (transaction code M) on September 15, 2026.
  • Tax withholding (first award): 1,024 shares were disposed of (transaction code F) at $3.56 per share on September 15, 2026.
  • RSU vesting (second award): 752 shares of Class A Common Stock were acquired via RSU conversion (transaction code M) on September 15, 2026.
  • Tax withholding (second award): 330 shares were disposed of (transaction code F) at $3.56 per share on September 15, 2026.
  • Resulting direct ownership: Fengler directly held 52,509 shares of Class A Common Stock following all reported transactions.
  • Remaining RSUs: 14,006 RSUs remain from the first award and 9,023 RSUs remain from the second award, both held directly.

RSU Vesting Details and Remaining Holdings for GoodRx's CFO

According to the filing, Justin Fengler, identified as Chief Financial Officer and Chief Strategy & Operations Officer of GoodRx Holdings, Inc., reported four transactions in Class A Common Stock on September 15, 2026. Two transactions involved the conversion of restricted stock units into shares (transaction code M), and two involved shares withheld to satisfy tax obligations (transaction code F), all at a price of $3.56 per share.

The filing describes two separate RSU awards. The first award vests "with respect to 1/16 of the award in quarterly installments on June 15, 2024 and on each quarterly anniversary thereafter," subject to Fengler's continued service through each vesting date. From this award, 2,335 RSUs were converted and 1,024 shares were withheld for taxes, leaving 14,006 RSUs outstanding. The second award vests "with respect to 1/16 of the award in quarterly installments on December 15, 2025 and on each quarterly anniversary thereafter," under the same continued-service condition. From this award, 752 RSUs were converted and 330 shares were withheld, leaving 9,023 RSUs outstanding.

The filing states that each restricted stock unit represents a contingent right to receive one share of Class A Common Stock. After all four transactions, Fengler's direct beneficial ownership of Class A Common Stock stood at 52,509 shares, according to the filing. The Form 4 was signed by Gracye Cheng as Attorney-in-Fact for Justin Fengler on September 15, 2026.

What Was Disclosed

The filing reported the vesting of two RSU tranche installments totaling 3,087 shares and the withholding of 1,354 shares at $3.56 each for tax purposes, resulting in Fengler directly owning 52,509 shares of GoodRx Class A Common Stock.